References
- Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23(1): 164–76
- Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 2001; 34(6): 1242–51
- Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105(1): 229–36
- Rector WG Jr. Hepatorenal syndrome. In: Gitnick GL, ed. Principles and practice of gastroenterology and hepatology. 2nd ed. Norwalk, Conn: Appleton & Lange, 1994: 881–6
- Arroyo V. New treatments for hepatorenal syndrome. (Editorial) Liver Transpl 2000; 6(3): 287–9
- Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36(4 Pt 1): 941–8
- Kaffy F, Borderie C, Chagneau C, et al. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. (Letter) J Hepatol 1999; 30(1): 174
- Pomier-Layrargues G, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003; 38(1): 238–43
- Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29(6): 1690–7
- Chojkier M, Groszmann RJ, Atterbury CE, et al. A controlled comparison of continuous intraarterial and intravenous infusions of vasopressin in hemorrhage from esophageal varices. Gastroenterology 1979; 77(3): 540–6
- Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27(1): 35–41
- Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33(1): 43–8
- Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicen- ter study. Gastroenterology 2002; 122(4): 923–30
- Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002; 36(2): 374–80
- Guevara M, Gines P, Bandi JC, et al. Trans- jugular intrahepatic portosystemic shunt in hepatorenal syndrome: effect on renal function and vasoactive systems. Hepatology 1998; 28(2): 416–22
- Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47(2): 288–95